What affordability assistance is available for my Patients taking Invokana®?
Janssen CarePath can help you find out what affordability assistance may be available for your patients taking INVOKANA®: Support for patients using commercial or private insurance: Eligible patients using commercial or private insurance can save on out-of-pocket costs for INVOKANA®.
When to increase the dose of Invokana ® 200 mg?
For patients with eGFR ≥60 mL/min/1.73 m 2, if an inducer of UGTs (eg, rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKANA ®, increase the dose to 200 mg (taken as two 100 mg tablets) once daily in patients currently tolerating INVOKANA ® 100 mg.
How can I get help paying for Invokana® and Invokamet® XR?
If you have commercial or private health insurance and need help paying for INVOKANA®, INVOKAMET® XR, and INVOKAMET®, the Janssen CarePath Savings Program may be able to help. If you don’t have commercial or private health insurance, you may find help from the programs and resources found on JanssenPrescriptionAssistance.com .
What are the contraindications for Invokana ®?
INVOKANA ® is contraindicated in patients with ESKD on dialysis. Hepatic Impairment: INVOKANA ® has not been studied in patients with severe hepatic impairment and is not recommended in this population. In the event of an overdose, contact the Poison Control Center and employ the usual supportive measures.
How do you save on Invokana?
Patients can text “SAVINGS” to 48798 (message and data rates may apply*) or use Express Enrollment at MyJanssenCarePath.com/Express to receive an electronic card that can be saved to their mobile wallet, or they can register for the Savings Program and sign up for ongoing support at INVOKANA.com.
Who makes INVOKANA?
RARITAN, N.J., March 29, 2013 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA™ (canagliflozin) for the treatment of adults with type 2 diabetes.
How do you get Invokana?
Or you may register at Invokana.com or by calling 877-INVOKANA (877-468-6526). The following programs are not affiliated with Janssen. Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.
How do you qualify for free eliquis?
You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:You have not previously filled a prescription for ELIQUIS;You have a valid 30-day prescription for ELIQUIS;You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;More items...
Is there a lawsuit against Invokana?
Currently, lawsuits have been filed against the makers of Invokana and other SGLT2 inhibitor manufacturers, claiming that the drugs cause acute interstitial nephritis, chronic kidney disease, end-stage renal disease, and acute kidney injuries.
Is there an alternative to Invokana?
Multiple brand-name drugs are on the market that are similar to Invokana. Just like Invokana, Farxiga and Jardiance are two SGLT2 inhibitors used to control blood sugar in those with type 2 diabetes. Both of these have been shown to lower A1C levels by as much as 1%, but they are expensive.
Why was Invokana taken off the market?
This information is an update to the FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) issued on May 16, 2017.
When will Invokana become generic?
Invokana was eligible for patent challenges on March 29, 2017. By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 11, 2031.
What are the dangers of Invokana?
Serious side effectsDehydration (low fluid level), which can cause low blood pressure. ... Hypoglycemia (low blood sugar level). ... Severe allergic reaction.*Amputation of lower limbs.*Diabetic ketoacidosis (increased levels of ketones in your blood or urine).*Fournier's gangrene (severe infection near the genitals).*More items...
How much is Eliquis at Walmart?
The cost of Eliquis is $695.91 for 60, 5MG Tablet, but you can use an Eliquis coupon below to pay $459.24 per 60, 5mg Tablet....Average 12 Month Prices for Eliquis.PharmacyEliquis Retail PriceEliquis SingleCare PriceWalmart$601.08$528.01Walgreens$623.72$537.78Kroger Pharmacy$624.91$487.613 more rows
What is a cheaper alternative to Eliquis?
You can always consider speaking to your provider to see if another, cheaper medication will be as effective as Eliquis for you. Similar anticoagulant medications to Eliquis include: Warfarin (Coumadin, Jantoven): Warfarin is a generic drug that is comparable with Eliquis but costs significantly less – as little as $4.
Does Bristol Myers Squibb have a patient assistance program?
The Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) is an independent, charitable organization that helps eligible patients who need temporary help obtaining the medicines listed on this website.
Why was Invokana taken off the market?
This information is an update to the FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) issued on May 16, 2017.
Is Invokana and Jardiance the same?
Invokana is in the same drug class but not exactly equivalent to Jardiance, Farxiga (dapagliflozin), and Steglatro (ertugliflozin).
What are the dangers of Invokana?
Serious side effectsDehydration (low fluid level), which can cause low blood pressure. ... Hypoglycemia (low blood sugar level). ... Severe allergic reaction.*Amputation of lower limbs.*Diabetic ketoacidosis (increased levels of ketones in your blood or urine).*Fournier's gangrene (severe infection near the genitals).*More items...
When will Invokana become generic?
Invokana was eligible for patent challenges on March 29, 2017. By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 11, 2031.
How to report INVOKANA side effects?from janssencarepath.com
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Scientific Affairs, LLC at 1-800-526-7736. Please read full Product Information and Medication Guide for INVOKANA®.
How to unsubscribe from Invokana?from invokana.com
You may unsubscribe from receiving further communications by following the instructions in the messages you receive, by following the unsubscribe link in any e-mail we send , or by calling 1-877-INVOKANA ( 1-877-468-6526 ).
What information is needed to register for Invokamet?from invokana.com
Before you register for the program, it is important that you understand that you will be asked to provide personal information that may include your name, address, phone number, email address, and information related to your prescription medication insurance and treatment. This information is necessary to permit Janssen Pharmaceuticals, Inc., the maker of INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR, and companies that work with Janssen Pharmaceuticals, Inc., including our affiliates and our service providers, to fulfill your request to register for the Janssen CarePath Savings Program. We may also use the information you give us to learn more about the people who use INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR, and to improve the information we provide to people who are being treated with INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR. Janssen Pharmaceuticals, Inc., will not share your information with anyone else except as required by law.
What is the Janssen CarePath Savings Program?from invokana.com
Janssen CarePath Savings Program for INVOKANA®, INVOKAMET® XR, and INVOKAMET® 1 Eligible commercial patients pay $0 per month for INVOKANA®, INVOKAMET® XR, and INVOKAMET®, subject to monthly program benefit limits. There is no limit to this benefit for your first month of treatment, and then a $200 limit for each month thereafter. There is a $3,000 maximum program benefit per calendar year.#N#Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. See full eligibility requirements . 2 When you register, you'll receive a Janssen CarePath Savings Program card. Download and print the card, and present the card at your pharmacy along with a valid prescription. Your eligibility to use this card is dependent upon meeting the program requirements each time you present the card when filling your prescription.
What is JJPAF in healthcare?from invokanahcp.com
(JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 800-652-6227 (Monday-Friday, 9:00 AM to 6:00 PM ET) or visit the foundation website at JJPAF.org .
How to contact Janssen Carepath Care Coordinator?from invokanahcp.com
Support for patients using government-funded healthcare programs or patients without insurance coverage: Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728) , or visit. JanssenPrescriptionAssistance.com for more information on affordability programs that may be available. Learn more.
How to use Janssen Carepath card?from invokana.com
When you register, you'll receive a Janssen CarePath Savings Program card. Download and print the card, and present the card at your pharmacy along with a valid prescription. Your eligibility to use this card is dependent upon meeting the program requirements each time you present the card when filling your prescription.
What to tell your doctor before taking Invokana?
Before taking INVOKANA®, tell your doctor if you:have a history of amputation; have heart disease or are at risk for heart disease; have had blocked or narrowed blood vessels (usually in leg); have damage to the nerves (neuropathy) in your leg; have had diabetic foot ulcers or sores; have kidney problems; have liver problems; have a history of urinary tract infections or problems with urination; are on a low sodium (salt) diet; are going to have surgery (your doctor may stop your INVOKANA®before you have surgery; talk to your doctor if you are having surgery about when to stop taking INVOKANA®and when to start it again); are eating less or there is a change in diet; have or have had pancreas problems; drink alcohol very often (or drink a lot of alcohol in the short-term); or ever had an allergic reaction to INVOKANA®.
Can INVOKANA cause dizziness?
Talk to your doctor about proper foot care. Dehydration. INVOKANA®can cause some people to become dehydrated (the loss of too much body water), which may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension).
Can INVOKANA cause amputation?
IMPORTANT SAFETY INFORMATION . INVOKANA®can cause serious side effects, including: Amputations. INVOKANA®may increase your risk of lower-limb amputations. Amputations mainly involve removal of the toe or part of the foot; however, amputations involving the leg, below and above the knee, have also occurred.
Can INVOKANA harm my baby?
Tell your doctor if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed. INVOKANA®may harm your unborn baby. If you become pregnant while taking INVOKANA®, tell your doctor right away. INVOKANA®may pass into your breast milk and may harm your baby. Do not breastfeed while taking INVOKANA®.
Is Invokana good for diabetics?
INVOKANA®is not for people with type 1 diabetes. It may increase their risk of diabetic ketoacidosis (increased ketones in blood or urine).
How to report INVOKANA side effects?
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Scientific Affairs, LLC at 1-800-526-7736. Please read full Product Information and Medication Guide for INVOKANA®.
What to tell your doctor before taking Invokana?
Before taking INVOKANA®, tell your doctor if you: have a history of amputation; have heart disease or are at risk for heart disease; have had blocked or narrowed blood vessels (usually in leg); have damage to the nerves (neuropathy) in your leg; have had diabetic foot ulcers or sores; have kidney problems; have liver problems; have a history of urinary tract infections or problems with urination; are on a low sodium (salt) diet; are going to have surgery (your doctor may stop your INVOKANA ® before you have surgery; talk to your doctor if you are having surgery about when to stop taking INVOKANA ® and when to start it again); are eating less or there is a change in diet; have or have had pancreas problems; drink alcohol very often (or drink a lot of alcohol in the short-term); or ever had an allergic reaction to INVOKANA ® .
Is Invokana safe for kidneys?
INVOKANA ® is not used to lower blood sugar (glucose) in adults with type 2 diabetes with severe kidney problems. It is not known if INVOKANA ® is safe and effective in children under 18 years of age. Amputations.
Can INVOKANA cause a burning sensation?
Serious Urinary Tract Infections: may lead to hospitalization and have happened in people taking INVOKANA ®. Tell your doctor if you have any signs or symptoms of a urinary tract infection such as: burning feeling while urinating, need to urinate often or right away, pain in the lower part of your stomach (pelvis), or blood in the urine. Some people may also have fever, back pain, nausea, or vomiting
Can INVOKANA harm my baby?
Tell your doctor if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed. INVOKANA ® may harm your unborn baby. If you become pregnant while taking INVOKANA ®, tell your doctor right away. INVOKANA ® may pass into your breast milk and may harm your baby.
Can INVOKANA cause dizziness?
INVOKANA® can cause some people to become dehydrated (the loss of too much body water), which may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). There have been reports of sudden worsening of kidney function in people with type 2 diabetes who are taking INVOKANA®.
Can INVOKANA cause low blood sugar?
Low blood sugar (hypoglycemia). If you take INVOKANA ® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher.
How many events per 1000 patients with Invokana?from accessdata.fda.gov
An increased risk of lower limb amputations associated with INVOKANA use versus placebo was observed in CANVAS (5.9 vs 2.8 events per 1000 patient-years) and CANVAS-R (7.5 vs 4.2 events per 1000 patient-years), two large, randomized, placebo-controlled trials in patients with type 2 diabetes who had established cardiovascular disease (CVD) or were at risk for CVD
What is Invokana used for?from accessdata.fda.gov
INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1) . Limitation of Use: . •Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis (1) .
What factors are considered before initiating INVOKANA?from accessdata.fda.gov
Before initiating INVOKANA, consider factors in the patient history that may predispose to ketoacidosis including pancreatic insulin deficiency from any cause, caloric restriction, and alcohol abuse. In patients treated with INVOKANA consider monitoring for ketoacidosis and temporarily discontinuing INVOKANA in clinical situations known to predispose to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery).
How long is Invokana trial?from drugs.com
A total of 714 type 2 diabetes patients ages 55 to 80 years and inadequately controlled on current diabetes therapy (either diet and exercise alone or in combination with oral or parenteral agents) participated in a 26-week, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Invokana in combination with current diabetes treatment. The mean age was 64 years, 55% of patients were men, and the mean baseline eGFR was 77 mL/min/1.73 m 2. Patients were randomized in a 1:1:1 ratio to the addition of Invokana 100 mg, Invokana 300 mg, or placebo, administered once daily. At the end of treatment, Invokana provided statistically significant improvements from baseline relative to placebo in HbA 1C (p<0.001 for both doses) of -0.57% (95% CI: -0.71%; -0.44%) for Invokana 100 mg and -0.70% (95% CI: -0.84%; -0.57%) for Invokana 300 mg. [see Use in Specific Populations (8.5)].
How long does canagliflozin suppress RT G?from drugs.com
From a starting RT G value of approximately 240 mg/dL, canagliflozin at 100 mg and 300 mg once daily suppressed RT G throughout the 24-hour period. Data from single oral doses of canagliflozin in healthy volunteers indicate that, on average, the elevation in urinary glucose excretion approaches baseline by about 3 days for doses up to 300 mg once daily. Maximal suppression of mean RT G over the 24-hour period was seen with the 300 mg daily dose to approximately 70 to 90 mg/dL in patients with type 2 diabetes in Phase 1 trials. The reductions in RT G led to increases in mean UGE of approximately 100 g/day in subjects with type 2 diabetes treated with either 100 mg or 300 mg of canagliflozin. In patients with type 2 diabetes given 100 to 300 mg once daily over a 16-day dosing period, reductions in RT G and increases in urinary glucose excretion were observed over the dosing period. In this trial, plasma glucose declined in a dose-dependent fashion within the first day of dosing. In single-dose trials in healthy and type 2 diabetic subjects, treatment with canagliflozin 300 mg before a mixed-meal delayed intestinal glucose absorption and reduced postprandial glucose.
What is the active ingredient in Invokana?from drugs.com
Invokana ® (canagliflozin) contains canagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. Canagliflozin, the active ingredient of Invokana, is chemically known as (1 S )-1,5-anhydro-1- [3- [ [5- (4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and its molecular formula and weight are C 24 H 25 FO 5 S∙1/2 H 2 O and 453.53, respectively. The structural formula for canagliflozin is:
How much Invokana is needed for a patient with a low eGFR?from accessdata.fda.gov
or greater and require additional glycemic control (2.1) •INVOKANA is limited to 100 mg once daily in patients who have an eGFR of 45 to less than 60 mL/min/1.73 m
How to contact Janssen Carepath Care Coordinator?
Support for patients using government-funded healthcare programs or patients without insurance coverage: Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728) , or visit. JanssenPrescriptionAssistance.com for more information on affordability programs that may be available. Learn more.
What is JJPAF in healthcare?
(JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 800-652-6227 (Monday-Friday, 9:00 AM to 6:00 PM ET) or visit the foundation website at JJPAF.org .
How to unsubscribe from Invokana?
You may unsubscribe from receiving further communications by following the instructions in the messages you receive, by following the unsubscribe link in any e-mail we send , or by calling 1-877-INVOKANA ( 1-877-468-6526 ).
What information is needed to register for Invokamet?
Before you register for the program, it is important that you understand that you will be asked to provide personal information that may include your name, address, phone number, email address, and information related to your prescription medication insurance and treatment. This information is necessary to permit Janssen Pharmaceuticals, Inc., the maker of INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR, and companies that work with Janssen Pharmaceuticals, Inc., including our affiliates and our service providers, to fulfill your request to register for the Janssen CarePath Savings Program. We may also use the information you give us to learn more about the people who use INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR, and to improve the information we provide to people who are being treated with INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR. Janssen Pharmaceuticals, Inc., will not share your information with anyone else except as required by law.
What is the Janssen CarePath Savings Program?
Janssen CarePath Savings Program for INVOKANA®, INVOKAMET® XR, and INVOKAMET® 1 Eligible commercial patients pay $0 per month for INVOKANA®, INVOKAMET® XR, and INVOKAMET®, subject to monthly program benefit limits. There is no limit to this benefit for your first month of treatment, and then a $200 limit for each month thereafter. There is a $3,000 maximum program benefit per calendar year.#N#Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. See full eligibility requirements . 2 When you register, you'll receive a Janssen CarePath Savings Program card. Download and print the card, and present the card at your pharmacy along with a valid prescription. Your eligibility to use this card is dependent upon meeting the program requirements each time you present the card when filling your prescription.
How to use Janssen Carepath card?
When you register, you'll receive a Janssen CarePath Savings Program card. Download and print the card, and present the card at your pharmacy along with a valid prescription. Your eligibility to use this card is dependent upon meeting the program requirements each time you present the card when filling your prescription.
Do I need to register my Janssen Carepath card?
Yes, I have a Janssen CarePath Savings Program card and I need to register it.
Is Janssen Carepath an extension?
Janssen CarePath is in no way an extension of medical treatment provided by healthcare professionals to individual patients. You may discontinue your participation at any time by calling 877-468-6526 . Please read and agree to the Janssen CarePath Savings Program Terms and Conditions.
What to do if you are not sure if your medicine is one listed above?from jnj.com
Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.
How old was the patient eligible for PAD?from jnj.com
Eligible patients were at least 50 years old and had documented symptomatic lower-extremity PAD. Patients were eligible after a successful revascularization for symptomatic PAD within the last 10 days. Approximately two-thirds were treated with an endovascular procedure (65%) and one-third treated surgically (35%). Patients were excluded if they were clinically unstable, at heightened bleeding risk, or needed prohibited concomitant medications, including long-term clopidogrel. The median age was 67 years and 26% were women. Common risk factors for PAD included diabetes, an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 (indicating mild-to-moderate kidney disease) and current smokers.
What is rivaroxaban used for?from janssencarepath.com
Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE:In patients with CrCl <30 mL/min, rivaroxaban exposure and pharmacodynamic effects are increased compared to patients with normal renal function. There are limited clinical data in patients with CrCl 15 to <30 mL/min; therefore, observe closely and promptly evaluate any signs or symptoms of blood loss in these patients. There are no clinical data in patients with CrCl <15 mL/min (including patients on dialysis); therefore, avoid the use of XARELTO®in these patients. Discontinue XARELTO®in patients who develop acute renal failure while on treatment.
How is Xarelto administered?from jnj.com
For both potential indications, XARELTO ® would be dosed based on body weight, either with an oral suspension formulation or tablets. The oral suspension formulation would be administered through a unique color-coded dosing device that was designed to help minimize dosing errors.
How to contact Harborpath?from jjpaf.org
or Call 1-800-652-6227. to have one mailed or faxed to you. If you’re taking HIV medications that aren’t covered by this program, please go to the HarborPath website to access the HarborPath Patient Application.
What is the tube called that is placed in your back to give you certain medicine?from jnj.com
o A thin tube called an epidural catheter is placed in your back to give you certain medicine
What is the largest study to date evaluating the treatment of pediatric patients with VTE?from jnj.com
Part of the industry leading EXPLORER clinical research program, EINSTEIN-Jr is the largest study completed to date evaluating the treatment of pediatric patients with VTE, and UNIVERSE is the first clinical trial to examine a DOAC for the prevention of thromboembolism in congenital heart disease post-Fontan pediatric patients.
How to unsubscribe from Invokana?from invokana.com
You may unsubscribe from receiving further communications by following the instructions in the messages you receive, by following the unsubscribe link in any e-mail we send , or by calling 1-877-INVOKANA ( 1-877-468-6526 ).
What information is needed to register for Invokamet?from invokana.com
Before you register for the program, it is important that you understand that you will be asked to provide personal information that may include your name, address, phone number, email address, and information related to your prescription medication insurance and treatment. This information is necessary to permit Janssen Pharmaceuticals, Inc., the maker of INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR, and companies that work with Janssen Pharmaceuticals, Inc., including our affiliates and our service providers, to fulfill your request to register for the Janssen CarePath Savings Program. We may also use the information you give us to learn more about the people who use INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR, and to improve the information we provide to people who are being treated with INVOKANA ®, INVOKAMET ®, and INVOKAMET ® XR. Janssen Pharmaceuticals, Inc., will not share your information with anyone else except as required by law.
What is the Janssen CarePath Savings Program?from invokana.com
Janssen CarePath Savings Program for INVOKANA®, INVOKAMET® XR, and INVOKAMET® 1 Eligible commercial patients pay $0 per month for INVOKANA®, INVOKAMET® XR, and INVOKAMET®, subject to monthly program benefit limits. There is no limit to this benefit for your first month of treatment, and then a $200 limit for each month thereafter. There is a $3,000 maximum program benefit per calendar year.#N#Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. See full eligibility requirements . 2 When you register, you'll receive a Janssen CarePath Savings Program card. Download and print the card, and present the card at your pharmacy along with a valid prescription. Your eligibility to use this card is dependent upon meeting the program requirements each time you present the card when filling your prescription.
What is Xarelto used for?from janssencarepath.com
XARELTO®, in combination with aspirin, is indicated to reduce the risk of major thrombotic vascular events (myocard ial infarction, ischemic stroke, acute limb ischemia , and major amputation of a vascular etiology) in patients with peripheral artery disease (PAD), including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD.
How much does Imbruvica cost?from drugs.com
The cost for Imbruvica oral capsule 140 mg is around $15,586 for a supply of 90 capsules, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. A generic version of Imbruvica has been approved by the FDA.
Is ketoacidosis a life threatening condition?from janssencarepath.com
Ketoacidosis: Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified in patients with type 1 and 2 diabetes mellitus receiving SGLT2 inhibitors, including INVOKANA ®. In placebo-controlled trials of patients with type 1 diabetes, the risk of ketoacidosis was increased in patients who received SGLT2 ...
Does Invokana cause renal volume depletion?from janssencarepath.com
Volume Depletion: INVOKANA ® can cause intravascular volume contraction, which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine. There have been postmarketing reports of acute kidney injury which are likely related to volume depletion, some requiring hospitalizations and dialysis, in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors, including INVOKANA ®. Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. Before initiating INVOKANA ® in patients with one or more of these characteristics, assess and correct volume status. Monitor for signs and symptoms of volume depletion after initiating therapy.